26 records, the earliest from 11 Nov 2020. As filed with the exchanges; the history is only as deep as the data Tradinity has collected.
26 shown.
Sign in to see more, or upgrade your plan to see the full history. Sign in
| Date | Purpose | Notes |
|---|---|---|
| 14 Aug 2026 | Financial Results | To consider and approve the unaudited limited reviewed financial results (standalone and consolidated) for the period ended June 30, 2026 and restated audited standalone and consolidated financial results for Quarter and Financial year ended March 31, 2026 on account of Scheme of Amalgamation coming into effect. |
| 1 Aug 2026 | Other business matters | Prior intimation of Board Meeting scheduled to be held on August 01, 2026 |
| 25 May 2026 | Financial Results | To consider and approve the financial results for the period ended March 31, 2026 |
| 11 Feb 2026 | Financial Results | To consider consider and approve Unaudited Limited Reviewed Financial Results (Standalone & Consolidated) of the Company for the Quarter-III of Financial Year 2025-26 ended on December 31, 2025. |
| 11 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 12 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
| 26 May 2025 | Financial Results | To consider and approve the financial results for the Quarter-IV and Financial Year ended on March 31, 2025 |
| 12 Feb 2025 | Financial Results | Orchid Pharma Ltd has informed NSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2025, inter alia, to consider and approve the financial results for the period ended December 31, 2024 |
| 11 Nov 2024 | Financial Results | To consider and approve the financial results for the period ended September 30, 2024 |
| 12 Aug 2024 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2024 |
Disclosures are shown as filed with the exchanges; Tradinity does not verify them. Nothing here is investment advice.
